Step by Step

2017/03/14 MGR: Randomized trials of chemotherapy for hormone-naïve metastatic prostate cancer: be careful what you wish for & Endocrine therapy duration updates: too much of a good thing?

INTRODUCTION

ABIM MOC Activity ID

3/14/2017 MGR: Randomized trials of chemotherapy for hormone-naïve metastatic prostate cancer: be careful what you wish for & Endocrine therapy duration updates: too much of a good thing?

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

Describe data supporting early chemotherapy in metastatic prostate cancer.
Review selection of patients for early chemotherapy for metastatic prostate cancer.
Identify risk factors for chemotherapy toxicity.
Review history of endocrine treatment
Describe difference in pre and post menopausal breast cancer.
Review new and updates in hormonal therapy.

Suggested Additional Reading:

Gnant, et al, Brit J Cancer, 2013.

Burstein HJ. J Clin Oncol 2014 32(21):2255-69.

Authors:

Leonard Appleman, MD, PhD — Associate Professor of Medicine Division of Hematology/Oncology, UPMC
Dr. Appleman receives grant/research support from Astellas BMS Bayer, Exelixis, Medivation, Cougar, Agensys, Pfizer, and Roche.

Shannon Puhalla, MD — Assistant Professor of Medicine Division of Hematology/Oncology, UPMC
Dr. Puhalla receives grant/research support from Abbvie, Pfizer, Lilly, Novartis, Incyte, Covance-Bayer, Eisai. She is a consultant with Abbvie, Medimmune, Alldex, and a board member with Alldex (DSMB)

No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.